congresses-banner
The content contained is subject
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
Disease Area Tab
PublicationView
Oral
Edoxaban
JCS 2024 | March 8-10, 2024
Assessment of long-term use versus discontinuation of direct oral anticoagulant after catheter ablation for atrial fibrillation
Poster
Edoxaban
ESC 2024 | August 30 – September 2, 2024
Association of R2-CHA2DS2-VASc score and clinical outcomes after bioprosthetic valve replacement:
Subanalysis from BPV-AF registry
Oral
Edoxaban
AHA 2023 | November 10-13, 2023
Clinical outcomes in TAVR patients receiving oral anticoagulation according to renal function: A prespecified analysis of the ENVISAGE-TAVI AF trial
Poster
Edoxaban
ESC 2024 | August 30 – September 2, 2024
Clinical outcomes of edoxaban treatment in atrial fibrillation patients with high bleeding risk:
Insights from the ETNA-AF-China 1-Year follow-up
Oral
Edoxaban
JCS 2024 | March 8-10, 2024
Current real-world status of off-label under- and over-dose of direct oral anticoagulants after atrial fibrillation ablation: RYOUMA registry sub-analysis
Poster
Edoxaban
EHRA 2024 | April 7-9, 2024
Decoding definitions of major bleeding in retrospective observational studies on direct oral anticoagulants for atrial fibrillation: A targeted literature review
Poster
Edoxaban
ESC 2024 | August 30 – September 2, 2024
Edoxaban dose, frailty, and outcomes in patients with atrial fibrillation: The ETNA-AF-Europe 4-year follow-up
Poster
Edoxaban
ESC 2024 | August 30 – September 2, 2024
Edoxaban for stroke prevention in routine practice patients with atrial fibrillation with and without atherosclerotic disease: A post hoc sub-study of ETNA-AF-Europe
Poster
Edoxaban
ESC 2024 | August 30 – September 2, 2024
Impact of body weight and body mass index on clinical outcomes of edoxaban therapy in atrial fibrillation patients included in the Global ETNA-AF programme
Poster
Edoxaban
ESC 2024 | August 30 – September 2, 2024
Impact of differences in body mass index, body surface area and lean body mass on clinical outcomes in patients with atrial fibrillation receiving edoxaban: 4-year follow-up data from ETNA-AF-Europe
Pages:
1 2